Philip Q Ding
Overview
Explore the profile of Philip Q Ding including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
31
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Goutam S, Stukalin I, Ewanchuk B, Sander M, Ding P, Meyers D, et al.
Curr Oncol
. 2022 Oct;
29(10):7695-7704.
PMID: 36290885
Immune checkpoint inhibitors (ICIs) for treatment of metastatic melanoma (MM) offer lasting overall survival (OS) benefit in a subset of patients. However, outcomes remain poor for non-responders. Clinical predictors of...
12.
Grosjean H, Dolter S, Meyers D, Ding P, Stukalin I, Goutam S, et al.
Curr Oncol
. 2021 Oct;
28(5):4213-4222.
PMID: 34677275
The emergence of immunotherapy revolutionized the treatment of non-small-cell-lung cancer (NSCLC), with multiple landmark clinical trials establishing the efficacy of these agents. However, many patients who receive immunotherapy in clinical...
13.
Rigo R, Doherty J, Koczka K, Kong S, Ding P, Cheng T, et al.
Curr Oncol
. 2021 Oct;
28(5):3978-3986.
PMID: 34677256
Immune checkpoint and MAP kinase pathway inhibitors can significantly improve long-term survival for patients with melanoma. There is limited real-world data of these regimens' effectiveness. We retrospectively analyzed 402 patients...
14.
Ding P, Batra A, Xu Y, McKinnon G, Cheung W
Clin Colorectal Cancer
. 2020 Apr;
19(3):209-218.
PMID: 32291245
Background: Even though obesity is a well-established risk factor for developing colon cancer, its prognostic value is not very well understood. The present study elucidated the effect of obesity, as...